Related Experiment Video
Updated: Jun 4, 2026
Characterization of Functionally Associated miRNAs in Glioblastoma and their Engineering into Artificial Clusters for Gene Therapy
Published on: October 4, 2019
Identification and functional characterization of glioma-specific promoters and their application in suicide gene
Toshio Yawata1, Yusuke Maeda, Makiko Okiku
1Department of Neurosurgery, Kochi Medical School, Nankoku, Kochi, Japan.
Abstract:
Suicide gene therapy has been shown to be effective in inducing tumor regression. In this study, a human brain tumor-specific promoter was identified and used to develop transcriptionally targeted gene therapy. We searched for genes with brain tumor-specific expression. By in silico and reverse-transcription polymerase chain reaction screening, MAGE-A3 and SSX4 were found to be expressed in a tumor-specific manner. SSX4 gene promoter activity was high in human brain tumor cells but not in normal human astrocyte cells, whereas the MAGE-A3 promoter showed activity in both tumor and normal cells. A retrovirus vector carrying a suicide gene, the herpes simplex virus thymidine kinase gene controlled by the SSX4 promoter, was constructed to evaluate the efficacy of the promoter in tumor-specific gene therapy. Glioma and human telomerase catalytic subunit-immortalized fibroblast BJ-5ta cell lines transduced with retrovirus vectors were assayed for killing activity by ganciclovir. Glioma cell lines were effectively killed by ganciclovir in a concentration-dependent manner, whereas BJ-5ta cells were not. By contrast, MAGE-A3 promoter failed to induce cytotoxicity in a brain tumor-specific manner. In addition, mouse glioma RSV-M cells transduced with retrovirus vector also showed suppressed tumor formation activity in syngeneic mice in response to ganciclovir administration. Therefore, the SSX4 promoter is a candidate for brain tumor-specific gene therapy and supports the efficacy and safety of suicide gene therapy for malignant brain tumors.
Insights
The SSX4 promoter shows promise for brain tumor-specific suicide gene therapy. This approach effectively targets glioma cells while sparing normal cells, indicating a potentially safer and more effective treatment for malignant brain tumors.
Area of Science:
- Oncology
- Gene Therapy
- Molecular Biology
Background:
- Suicide gene therapy is a promising strategy for inducing tumor regression.
- Targeted gene delivery is crucial for maximizing efficacy and minimizing side effects.
Purpose of the Study:
- To identify and validate a brain tumor-specific promoter for targeted suicide gene therapy.
- To evaluate the efficacy and safety of the SSX4 promoter in preclinical models of brain tumors.
Main Methods:
- In silico and RT-PCR screening identified MAGE-A3 and SSX4 for tumor-specific expression.
- A retroviral vector with the SSX4 promoter driving the herpes simplex virus thymidine kinase suicide gene was constructed.
- Cytotoxicity assays in glioma and normal cell lines, and in vivo studies in mice were performed.
Main Results:
- The SSX4 promoter exhibited high activity in human brain tumor cells but not normal astrocytes.
- Ganciclovir treatment effectively killed SSX4 promoter-driven suicide gene-transduced glioma cells in a dose-dependent manner.
- SSX4 promoter-based therapy suppressed tumor formation in mouse glioma models, with no observed toxicity in normal cells.
Conclusions:
- The SSX4 promoter is a viable candidate for achieving brain tumor-specific gene therapy.
- This study demonstrates the efficacy and safety of SSX4 promoter-driven suicide gene therapy for malignant brain tumors.
More Related Videos
12:52Isolation and Flow Cytometric Analysis of Glioma-infiltrating Peripheral Blood Mononuclear Cells
Published on: November 28, 2015
10:58Transposon Mediated Integration of Plasmid DNA into the Subventricular Zone of Neonatal Mice to Generate Novel Models of Glioblastoma
Published on: February 22, 2015